| pubmed-article:1379394 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1379394 | lifeskim:mentions | umls-concept:C0166049 | lld:lifeskim |
| pubmed-article:1379394 | lifeskim:mentions | umls-concept:C0312418 | lld:lifeskim |
| pubmed-article:1379394 | lifeskim:mentions | umls-concept:C0014441 | lld:lifeskim |
| pubmed-article:1379394 | lifeskim:mentions | umls-concept:C0036667 | lld:lifeskim |
| pubmed-article:1379394 | lifeskim:mentions | umls-concept:C0079411 | lld:lifeskim |
| pubmed-article:1379394 | lifeskim:mentions | umls-concept:C2349975 | lld:lifeskim |
| pubmed-article:1379394 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:1379394 | pubmed:dateCreated | 1992-8-28 | lld:pubmed |
| pubmed-article:1379394 | pubmed:abstractText | A second generation ELISA for combined detection of antibodies to three hepatitis C virus (HCV) recombinant proteins, i.e. C100, C33c and core, was compared with a first generation anti-HCV ELISA in which only antibodies to C100 are detected. The results of the ELISAs were evaluated in 225 haemophilia patients (panel A) and 44 patients with non-A, non-B (NANB) hepatitis (panel B). HCV infection was established by cDNA-polymerase chain reaction (PCR) (in panel B only) and by studying the anti-HCV reaction patterns in 4 separate ELISAs for detection of antibodies to the recombinant proteins C100, C33c, core and a combination of two synthetic peptides sp67/65 derived from the C100 region. The sensitivity for the detection of HCV infection had increased from 0.92[95% confidence interval (CI): 0.87-0.95] to 1.00 (95% CI: 0.89-1.00) in haemophiliacs and from 0.84 (95% CI: 0.66-0.95) to 1.00 (95% CI: 0.89-1.00) in NANB hepatitis patients when the second generation ELISA was used instead of the first generation ELISA. Concurrently the chance of a false negative result was reduced in panel A and B from 0.37 to 0 and from 0.28 to 0, respectively. Analysis of anti-HCV reaction patterns revealed that 172 of 206 (83.5%) anti-HCV ELISA-reactive haemophilia patients had antibodies to all 4 antigens tested. In the NANB hepatitis patients 18 of 31 (58.1%) anti-HCV ELISA-reactive subjects reacted with 4 antigens. In the PCR tested panel of NANB hepatitis patients 2 subjects who showed antibody reactivity to only one antigen and 5 patients with reactivity to 2 antigens were PCR-positive.(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:1379394 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1379394 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1379394 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1379394 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1379394 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1379394 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1379394 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1379394 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1379394 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1379394 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1379394 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1379394 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1379394 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1379394 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1379394 | pubmed:issn | 0042-9007 | lld:pubmed |
| pubmed-article:1379394 | pubmed:author | pubmed-author:ReesinkH WHW | lld:pubmed |
| pubmed-article:1379394 | pubmed:author | pubmed-author:KutHH | lld:pubmed |
| pubmed-article:1379394 | pubmed:author | pubmed-author:HoughtonMM | lld:pubmed |
| pubmed-article:1379394 | pubmed:author | pubmed-author:CuypersH THT | lld:pubmed |
| pubmed-article:1379394 | pubmed:author | pubmed-author:ChooQ LQL | lld:pubmed |
| pubmed-article:1379394 | pubmed:author | pubmed-author:Mauser-Bunsch... | lld:pubmed |
| pubmed-article:1379394 | pubmed:author | pubmed-author:van der... | lld:pubmed |
| pubmed-article:1379394 | pubmed:author | pubmed-author:BrestersDD | lld:pubmed |
| pubmed-article:1379394 | pubmed:author | pubmed-author:SchaasbergW... | lld:pubmed |
| pubmed-article:1379394 | pubmed:author | pubmed-author:LesniewskiRR | lld:pubmed |
| pubmed-article:1379394 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1379394 | pubmed:volume | 62 | lld:pubmed |
| pubmed-article:1379394 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1379394 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:1379394 | pubmed:pagination | 213-7 | lld:pubmed |
| pubmed-article:1379394 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1379394 | pubmed:meshHeading | pubmed-meshheading:1379394-... | lld:pubmed |
| pubmed-article:1379394 | pubmed:meshHeading | pubmed-meshheading:1379394-... | lld:pubmed |
| pubmed-article:1379394 | pubmed:meshHeading | pubmed-meshheading:1379394-... | lld:pubmed |
| pubmed-article:1379394 | pubmed:meshHeading | pubmed-meshheading:1379394-... | lld:pubmed |
| pubmed-article:1379394 | pubmed:meshHeading | pubmed-meshheading:1379394-... | lld:pubmed |
| pubmed-article:1379394 | pubmed:meshHeading | pubmed-meshheading:1379394-... | lld:pubmed |
| pubmed-article:1379394 | pubmed:meshHeading | pubmed-meshheading:1379394-... | lld:pubmed |
| pubmed-article:1379394 | pubmed:meshHeading | pubmed-meshheading:1379394-... | lld:pubmed |
| pubmed-article:1379394 | pubmed:meshHeading | pubmed-meshheading:1379394-... | lld:pubmed |
| pubmed-article:1379394 | pubmed:meshHeading | pubmed-meshheading:1379394-... | lld:pubmed |
| pubmed-article:1379394 | pubmed:meshHeading | pubmed-meshheading:1379394-... | lld:pubmed |
| pubmed-article:1379394 | pubmed:meshHeading | pubmed-meshheading:1379394-... | lld:pubmed |
| pubmed-article:1379394 | pubmed:meshHeading | pubmed-meshheading:1379394-... | lld:pubmed |
| pubmed-article:1379394 | pubmed:meshHeading | pubmed-meshheading:1379394-... | lld:pubmed |
| pubmed-article:1379394 | pubmed:meshHeading | pubmed-meshheading:1379394-... | lld:pubmed |
| pubmed-article:1379394 | pubmed:meshHeading | pubmed-meshheading:1379394-... | lld:pubmed |
| pubmed-article:1379394 | pubmed:meshHeading | pubmed-meshheading:1379394-... | lld:pubmed |
| pubmed-article:1379394 | pubmed:meshHeading | pubmed-meshheading:1379394-... | lld:pubmed |
| pubmed-article:1379394 | pubmed:meshHeading | pubmed-meshheading:1379394-... | lld:pubmed |
| pubmed-article:1379394 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1379394 | pubmed:articleTitle | Enhanced sensitivity of a second generation ELISA for antibody to hepatitis C virus. | lld:pubmed |
| pubmed-article:1379394 | pubmed:affiliation | Central Laboratory of The Netherlands, Red Cross Blood Transfusion Service, Amsterdam, The Netherlands. | lld:pubmed |
| pubmed-article:1379394 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1379394 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1379394 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1379394 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1379394 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1379394 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1379394 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1379394 | lld:pubmed |
